Incyte Clocks Mixed Q3 Earnings, But Analyst Sees A Strong Quarter For Jakafi And Opzelura

On Tuesday, Incyte Corporation INCY reported third-quarter revenue of $1.14 billion, up 24$1.08 billion. The company reported adjusted EPS of $1.07, down from$1.10 a year ago and missing the consensus estimate of $1.09. Jakafi (ruxolitinib) net product revenues increased to$741.18 million, up 16% year over year, primarily due to a 10% increase in total demand. Channel inventory at the end of the third quarter of 2024 was within the normal range. For the quarte ...